269 related articles for article (PubMed ID: 29105153)
1. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
4. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
5. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
6. Genetic therapies for inherited neuromuscular disorders.
Scoto M; Finkel R; Mercuri E; Muntoni F
Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
[TBL] [Abstract][Full Text] [Related]
7. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
8. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
Amanat M; Nemeth CL; Fine AS; Leung DG; Fatemi A
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365206
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides and other genetic therapies made simple.
Rossor AM; Reilly MM; Sleigh JN
Pract Neurol; 2018 Apr; 18(2):126-131. PubMed ID: 29455156
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
Verma A
Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
[TBL] [Abstract][Full Text] [Related]
12. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.
Goyenvalle A; Leumann C; Garcia L
J Neuromuscul Dis; 2016 May; 3(2):157-167. PubMed ID: 27854216
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
15. [Innovative therapeutic approaches for hereditary neuromuscular diseases].
Kirschner J; Schoser B
Nervenarzt; 2018 Oct; 89(10):1115-1122. PubMed ID: 30171303
[TBL] [Abstract][Full Text] [Related]
16. An update on RNA-targeting therapies for neuromuscular disorders.
Jirka S; Aartsma-Rus A
Curr Opin Neurol; 2015 Oct; 28(5):515-21. PubMed ID: 26280937
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
18. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
19. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
